Skip to main content
Clinical Trials/ISRCTN86065299
ISRCTN86065299
Completed
Not Applicable

The effect of a disease-specific supplement on the postprandial plasma glucose response in type 2 diabetic patients at baseline and after 6 and 12 weeks of supplementatio

umico Research B.V. (The Netherlands)0 sites34 target enrollmentJune 7, 2006

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes Mellitus type II (DM type II)
Sponsor
umico Research B.V. (The Netherlands)
Enrollment
34
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 7, 2006
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
umico Research B.V. (The Netherlands)

Eligibility Criteria

Inclusion Criteria

  • 1\. Diagnosis type 2 diabetes
  • 2\. Age \>18
  • 3\. HbA1c between 6\.5% \- 8\.5%
  • 4\. Anti\-diabetic therapy: metformin and/or sulfonylureas
  • 5\. In need of nutritional support
  • 6\. Capable of using oral drink feed supplementation
  • 7\. On a stable and controlled anti\-diabetic regime for at least one month
  • 8\. Signed informed consent

Exclusion Criteria

  • 1\. Pregnant or lactating woman or woman planning to become pregnant
  • 2\. Usage of a disease\-specific nutritional supplement within past four weeks
  • 5\. Concomitant therapy with systemic glucocorticoids, insulin or anti\-diabetic medication other than metformin or sulfonylureas
  • 6\. Any acute gastrointestinal disease within two weeks prior to study entry
  • 7\. Gastrectomy, gastroparesis or other gastric emptying abnormalities
  • 8\. Acute severe heart failure, end stage liver failure or renal failure requiring dialysis
  • 9\. Patients receiving enteral nutrition
  • 10\. Patients with galactosaemia, fructosaemia or patients requiring a fibre\-free diet
  • 11\. Drug or alcohol abuse
  • 12\. Participation in other trials within 4 weeks of study entry

Outcomes

Primary Outcomes

Not specified

Similar Trials